These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11892539)

  • 1. New vaccine technology--what do you need to know?
    Minichiello V
    J Am Acad Nurse Pract; 2002 Feb; 14(2):73-81. PubMed ID: 11892539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of new technologies on vaccines.
    Talwar GP; Diwan M; Razvi F; Malhotra R
    Natl Med J India; 1999; 12(6):274-80. PubMed ID: 10732430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity under the skin: potential application for topical delivery of vaccines.
    Partidos CD; Beignon AS; Mawas F; Belliard G; Briand JP; Muller S
    Vaccine; 2003 Jan; 21(7-8):776-80. PubMed ID: 12531358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled delivery of antigens and adjuvants in vaccine development.
    Zhao Z; Leong KW
    J Pharm Sci; 1996 Dec; 85(12):1261-70. PubMed ID: 8961136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.
    Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR
    Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for DNA vaccine delivery.
    Alpar HO; Papanicolaou I; Bramwell VW
    Expert Opin Drug Deliv; 2005 Sep; 2(5):829-42. PubMed ID: 16296781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microneedle Patches as Drug and Vaccine Delivery Platform.
    Li J; Zeng M; Shan H; Tong C
    Curr Med Chem; 2017; 24(22):2413-2422. PubMed ID: 28552053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.
    Vajdy M; Srivastava I; Polo J; Donnelly J; O'Hagan D; Singh M
    Immunol Cell Biol; 2004 Dec; 82(6):617-27. PubMed ID: 15550120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.
    Deering RP; Kommareddy S; Ulmer JB; Brito LA; Geall AJ
    Expert Opin Drug Deliv; 2014 Jun; 11(6):885-99. PubMed ID: 24665982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does concomitant injection of a combined diphtheria-tetanus-acellular pertussis - hepatitis B virus - inactivated polio virus vaccine influence the reactogenicity and immunogenicity of commercial Haemophilus influenzae type b conjugate vaccines?
    Usonis V; Bakasenas V
    Eur J Pediatr; 1999 May; 158(5):398-402. PubMed ID: 10333123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine process technology.
    Josefsberg JO; Buckland B
    Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA-launched live-attenuated vaccines for biodefense applications.
    Pushko P; Lukashevich IS; Weaver SC; Tretyakova I
    Expert Rev Vaccines; 2016 Sep; 15(9):1223-34. PubMed ID: 27055100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-viral vector as vaccine carrier.
    Chen WC; Huang L
    Adv Genet; 2005; 54():315-37. PubMed ID: 16096017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically engineered vaccines: an overview.
    Dertzbaugh MT
    Plasmid; 1998; 39(2):100-13. PubMed ID: 9514708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-sized vaccine delivery systems.
    Scheerlinck JP; Greenwood DL
    Drug Discov Today; 2008 Oct; 13(19-20):882-7. PubMed ID: 18656548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
    Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.
    Chevallier B; Vesikari T; Brzostek J; Knuf M; Bermal N; Aristegui J; Borys D; Cleerbout J; Lommel P; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S109-18. PubMed ID: 19325447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.